Microbial Bioactives
Microbial Bioactives | Online ISSN 2209-2161
380
Citations
257k
Views
185
Articles
Volume 9 Number 1 2026
REVIEWS (Open Access)
Systematic Review and Quantitative Comparative Analysis of Antimicrobial Efficacy, Target Binding, and Resistance Profiles of iChip-Derived Compounds, Including Teixobactin and Its Analogs
Maryam Zafar 1*, Faiz un-Nisa 2, Bheesham Kingrani 3, Md. Sajib Hossain Suvo 4
Microbial Bioactives 9 (1) 1-17 https://doi.org/10.25163/microbbioacts.9110743
Submitted: 26 March 2026 Revised: 21 May 2026 Accepted: 29 May 2026 Published: 31 May 2026
Abstract
The accelerating crisis of antimicrobial resistance (AMR) has, in recent years, forced a reconsideration of how antibiotics are discovered, optimized, and ultimately deployed. Within this shifting landscape, iChip technology—by enabling access to previously unculturable microorganisms—has emerged as a quietly transformative tool. This systematic review and quantitative comparative synthesis attempts to bring some coherence to an otherwise fragmented body of literature surrounding iChip-derived antibiotics, particularly teixobactin and its analogues. Sixteen studies were systematically identified and analyzed under the PRISMA 2020 framework, integrating antimicrobial activity (MIC), target-binding interactions, resistance dynamics, and translational outcomes. The findings, perhaps unsurprisingly yet still striking, confirm that teixobactin maintains exceptional potency against Gram-positive pathogens, often at sub-microgram levels. And yet, the story does not remain so straightforward. Synthetic analogues—while more accessible—frequently display reduced efficacy, suggesting a delicate dependence on structural precision. More intriguingly, the relationship between binding affinity and antimicrobial activity appears inconsistent, hinting that efficacy extends beyond simple target engagement. Resistance, long considered negligible, emerges instead as a low-probability but tangible outcome, often mediated through tolerance pathways rather than direct mutation. Taken together, these results suggest that iChip-derived antibiotics represent not a definitive solution, but rather an evolving paradigm—one defined as much by its promise as by its complexity.
Keywords: iChip technology; Teixobactin; Antimicrobial resistance; Lipid II binding; Antibiotic discovery; Structure–activity relationship; Resistance tolerance
References
Amin, R. B., Setu, S. N., & Mia, R. (2025). Advances in CAR T-Cell Engineering and Redirected Immune Effector Cells for Enhanced Solid Tumor Immunotherapy: A Systematic Review. Journal of Precision Biosciences, 7(1), 1–8, 10540. https://doi.org/10.25163/biosciences.7110540
Berdy, B., Spoering, A. L., Ling, L. L., & Epstein, S. S. (2017). In situ cultivation of previously uncultivable microorganisms using the ichip. Nature Protocols, 12(10), 2232–2242. https://doi.org/10.1038/nprot.2017.074
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009). Introduction to meta-analysis. Wiley. https://doi.org/10.1002/9780470743386
Brüssow, H. (2024). The antibiotic resistance crisis and the development of new antibiotics. Microbial Biotechnology, 17(7), e14510. https://doi.org/10.1111/1751-7915.14510
Cardona, S. T., Rahman, A. S. M. Z., & Nechcoff, J. N. (2025). Innovative perspectives on the discovery of small molecule antibiotics. Nature Reviews Chemistry. https://doi.org/10.1038/s44259-025-00089-0
Chiorean, S., Antwi, I., Carney, D. W., Kotsogianni, I., Giltrap, A. M., Alexander, F. M., Cochrane, S. A., Payne, R. J., Martin, N. I., Henninot, A., & Vederas, J. C. (2020). Dissecting the binding interactions of teixobactin with the bacterial cell wall precursor lipid II. ChemBioChem, 21(6), 789–792. https://doi.org/10.1002/cbic.201900504
Darnell, R. L., Knottenbelt, M. K., Todd Rose, F. O., Monk, I. R., Stinear, T. P., & Cook, G. M. (2019). Genomewide profiling of the Enterococcus faecalis transcriptional response to teixobactin reveals CroRS as an essential regulator of antimicrobial tolerance. mSphere, 4(3), e00228-19. https://doi.org/10.1128/mSphere.00228-19
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188. https://doi.org/10.1016/0197-2456(86)90046-2
Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634. https://doi.org/10.1136/bmj.315.7109.629
Geers, A. U., Buijs, Y., Strube, M. L., et al. (2022). Evaluating biosynthesis potential of unculturable microbes. Computational and Structural Biotechnology Journal, 20, 343–352. https://doi.org/10.1016/j.csbj.2021.12.024
Hidat, S. D., Masatu, J., Masota, N. E., Mwakalukwa, R., Malaba, P., Sempombe, J., & Mloka, D. (2026). Combining isolation chips with velvet transfer for high-throughput primary screening of antibiotic-producing soil-dwelling bacteria. Journal of Microbiological Methods, 242, 107397. https://doi.org/10.1016/j.mimet.2026.107397
Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (2022). Cochrane handbook for systematic reviews of interventions (Version 6.3). Cochrane. http://www.training.cochrane.org/handbook
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560. https://doi.org/10.1136/bmj.327.7414.557
Homma, T., Nuxoll, A., Gandt, A. B., et al. (2016). Dual targeting of cell wall precursors by teixobactin. Antimicrobial Agents and Chemotherapy, 60(11), 6510–6517. https://doi.org/10.1128/AAC.01050-16
Imai, Y., Meyer, K. J., Iinishi, A., et al. (2019). A new antibiotic selectively kills Gram-negative pathogens. Nature, 576(7787), 459–464. https://doi.org/10.1038/s41586-019-1791-1
Iyer, A., Madder, A., & Singh, I. (2019). Teixobactins: A new class of 21st century antibiotics to combat multidrug-resistant bacterial pathogens. Future Microbiology, 14(6), 457–460. https://doi.org/10.2217/fmb-2019-0056
Jarkhi, A., Lee, A. H. C., Sun, Z., Hu, M., Neelakantan, P., Li, X., & Zhang, C. (2022). Antimicrobial effects of L-Chg10-teixobactin against Enterococcus faecalis in vitro. Microorganisms, 10(6), 1099. https://doi.org/10.3390/microorganisms10061099
Klahn, P., & Brönstrup, M. (2017). New structural templates in antimicrobial research. Natural Product Reports.
Lawrence, W. S., Peel, J. E., de Winter, R., Ling, L. L., Nitti, A. G., Peoples, A. J., Shukla, R., MacGillavry, H. D., Heine, H. S., & Hensel, M. E. (2025). Teixobactin: A resistance-evading antibiotic for treating anthrax. ACS Infectious Diseases, 11(3), 727–737. https://doi.org/10.1021/acsinfecdis.4c00835
Lewis, K. (2020). The science of antibiotic discovery. Cell, 181(1), 29–45. https://doi.org/10.1016/j.cell.2020.02.056
Ling, L. L., Schneider, T., Peoples, A. J., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature, 517(7535), 455–459. https://doi.org/10.1038/nature14098
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., Jones, M., Lazarides, L., Steadman, V. A., Cohen, D. R., Felix, C. R., Fetterman, K. A., Millett, W. P., Nitti, A. G., Zullo, A. M., Chen, C., & Lewis, K. (2015). A new antibiotic kills pathogens without detectable resistance. Nature, 517(7535), 455–459. https://doi.org/10.1038/nature14098
Lloyd, D. G., Schofield, B. J., Goddard, M. R., & Taylor, E. J. (2021). De novo resistance to Arg10-teixobactin occurs slowly and is costly. Antimicrobial Agents and Chemotherapy, 65(1), e01152-20. https://doi.org/10.1128/AAC.01152-20
Matos de Opitz, C. L., & Sass, P. (2020). Exploring new mechanisms of antibiotic action. Future Microbiology, 15(9), 703–708. https://doi.org/10.2217/fmb-2020-0048
McCarthy, M. W. (2019). Teixobactin as a novel anti-infective. Expert Review of Anti-infective Therapy, 17(1), 1–3. https://doi.org/10.1080/14787210.2019.1550357
Murray, C. J., Ikuta, K. S., Sharara, F., et al. (2022). Global burden of bacterial antimicrobial resistance. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
Ng, V., Kuehne, S. A., & Chan, W. C. (2018a). Modified teixobactin analogues. Chemistry – A European Journal, 24, 9136–9147. https://doi.org/10.1002/chem.201801423
Ng, V., Kuehne, S. A., & Chan, W. C. (2018b). Rational design and synthesis of modified teixobactin analogues: In vitro antibacterial activity against Staphylococcus aureus, Propionibacterium acnes and Pseudomonas aeruginosa. Chemistry – A European Journal, 24(37), 9136–9147. https://doi.org/10.1002/chem.201801423
Nichols, D., Cahoon, N., Trakhtenberg, E. M., et al. (2010). Use of iChip for microbial cultivation. Applied and Environmental Microbiology, 76(8), 2445–2450. https://doi.org/10.1128/AEM.01754-09
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Piddock, L. J. V. (2015). Teixobactin as a new antibiotic class. Journal of Antimicrobial Chemotherapy, 70(10), 2679–2680. https://doi.org/10.1093/jac/dkv175
Prakasam, G., Ramamoorthi, R., & Gopi, M. (2026). Teixobactin and darobactin: Dual breakthroughs in new antibiotic classes against MDR pathogens. International Journal of Life Sciences, Biotechnology and Pharma Research, 15(1), 810–818.
Qi, Y. K., Ai, H. S., Li, Y. M., & Yan, B. (2022). Teixobactin as a new antibiotic class. Journal of Peptide Science, 28(11), e3428. https://doi.org/10.1002/psc.3428
Ramchuran, E. J., Somboro, A. M., Abdel Monaim, S. A. H., Amoako, D. G., Parboosing, R., Kumalo, H. M., Agrawal, N., Albericio, F., de La Torre, B. G., & Bester, L. A. (2018). In vitro antibacterial activity of teixobactin derivatives on clinically relevant bacterial isolates. Frontiers in Microbiology, 9, 1535. https://doi.org/10.3389/fmicb.2018.01535
Ramchuran, E. J., Somboro, A. M., Abdel Monaim, S. A. H., et al. (2018). Antibacterial activity of teixobactin derivatives. Frontiers in Microbiology, 9, 1535. https://doi.org/10.3389/fmicb.2018.01535
Setu, S. N., Amin, R. B., & Mia, R. (2025). Benchmarking the Omics Revolution: A Comprehensive Review of Methodological Consistency and Clinical Readiness. Journal of Precision Biosciences, 7(1), 1–11. https://doi.org/10.25163/biosciences.7110539
Shukla, R., Lavore, F., Maity, S., Derks, M. G. N., Jones, C. R., Vermeulen, B. J. A., Melcrová, A., Morris, M. A., Becker, L. M., Wang, X., Kumar, R., Medeiros-Silva, J., van Beekveld, R. A. M., Bonvin, A. M. J. J., Lorent, J. H., Lelli, M., Nowick, J. S., MacGillavry, H. D., Peoples, A. J., Spoering, A. L., Ling, L. L., Hughes, D. E., Roos, W. H., Breukink, E., Lewis, K., & Weingarth, M. (2022). Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature, 608(7922), 390–396. https://doi.org/10.1038/s41586-022-05019-y
Shukla, R., Lavore, F., Maity, S., et al. (2022). Teixobactin mechanism of action. Nature, 608(7922), 390–396. https://doi.org/10.1038/s41586-022-05019-y
Shukla, R., Peoples, A. J., Ludwig, K. C., et al. (2023). Clovibactin discovery. Cell, 186(19), 4059–4073. https://doi.org/10.1016/j.cell.2023.07.038
Todd Rose, F. O., Darnell, R. L., Morris, S. M., Rose, O. E., Paxie, O., Campbell, G., Cook, G. M., & Gebhard, S. (2023a). The two-component system CroRS acts as a master regulator of cell envelope homeostasis to confer antimicrobial tolerance in the bacterial pathogen Enterococcus faecalis. Molecular Microbiology, 120, 408–424. https://doi.org/10.1111/mmi.15128
Todd Rose, F. O., et al. (2023b). CroRS regulatory system in teixobactin response. Molecular Microbiology.
Velkov, T., & Karas, J. A. (2020). Structure-activity relationships of teixobactin. Annals of the New York Academy of Sciences, 1459(1), 86–105. https://doi.org/10.1111/nyas.14282
Recommended articles
Yeast-Derived Biomolecules in Green Nanotechnology: Bridging Sustainable Bioeconomy and Early-Life Antimicrobial Resistance Management
Environmental Dissemination of Antimicrobial Resistance in Rice Paddy Ecosystems Irrigated with Reclaimed Water
2
Save
Save
0
Citation
Citation
9
View
View
0
Share
Share